查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1978847

Sunitinib酸鹽市場：按適應症、治療階段、最終用戶和分銷管道分類 - 全球預測，2026-2032 年

Sunitinib Malate Market by Indication, Line Of Treatment, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年Sunitinib酸鹽市值為 1.4843 億美元，預計到 2026 年將成長至 1.6695 億美元，複合年成長率為 11.69%，到 2032 年將達到 3.2201 億美元。

主要市場統計數據
基準年 2025 1.4843億美元
預計年份：2026年 1.6695億美元
預測年份：2032年 3.2201億美元
複合年成長率 (%) 11.69%

本書清晰而權威地介紹了Sunitinib替尼的治療作用，以及影響腫瘤學臨床和商業性決策的策略考量。

Sunitinib酸鹽已成為多種腫瘤適應症的基礎標標靶治療。鑑於其近期的臨床和商業性進展，有必要對其進行簡明扼要的管理概述。本文概述了該化合物的治療特性，重點闡述其多靶點受體蛋白酪氨酸激酶抑制活性及其在血管生成和致癌性訊號通路是疾病進展主要促進因素的疾病中的臨床意義。以下分析將舒尼替尼置於不斷發展的治療範式、監管對話和相關人員期望的背景下，並著重於Sunitinib證據與商業策略之間的相互作用。

精準診斷、口服抗癌藥物治療模式的進步以及不斷變化的支付方環境，是如何重新定義臨床定位和商業策略的？

標靶癌症治療領域正經歷變革性的轉變，其影響範圍不僅限於新型分子藥物的引入，還涵蓋了診斷、醫療服務和支付方趨勢。精準腫瘤學不斷改變治療選擇的方向，更精細的基因組和表現型特徵分析使得Sunitinib等藥物能夠針對不同的腫瘤亞型進行差異化應用。隨著生物標記的進步，口服抗癌藥物的興起正在改變患者管理的模式，門診管道、用藥依從性策略和遠端監測技術的重要性日益凸顯。

評估美國關稅措施對供應鏈韌性、採購和市場進入。

對源自美國或經美國轉運的藥品原料和成品徵收關稅，將對全球供應鏈和商業營運產生實際影響。當關稅影響活性成分、成品製劑或原料時，製造商可能面臨生產成本增加，而這些影響會影響採購、生產週期和庫存策略。因此，在合約和監管限制價格柔軟性的市場中，銷售部門必須重新評估其定價策略、與分銷商的談判以及商店的價格定位。

詳細的細分揭示了適應症、治療方案、醫療機構和分銷管道如何影響臨床應用案例和商業性重點。

一套精細的細分框架揭示了Sunitinib在不同臨床環境和商業管道中的使用和價值提案的差異。在適應症層面進行區分，可以清楚地識別生物學亞組和治療目標。胃腸道基質腫瘤（GIST）包括KIT突變型、PDGFRα突變型和野生型腫瘤，它們對激酶抑制劑的反應各不相同。同時，胰臟神經內分泌腫瘤（PNET）分為功能性和非功能性兩種狀態，其症狀負擔和治療目標也存在差異；腎細胞癌則分為透明細胞癌和非透明細胞癌兩種組織學類型，其預後和治療方案也存在差異。這種適應症層面的分層會影響臨床決策、臨床實驗室設計以及伴隨診斷策略的發展。

區域監管差異、支付方模式和分銷基礎設施如何推動美洲、歐洲、中東、非洲和亞太地區採取差異化的准入策略？

區域趨勢正對全球監管管道、報銷標準和相關人員的期望產生重大影響。在美洲，監管機構和支付方關注的是相對臨床獲益和成本效益，而醫療保健系統則涵蓋了從高度集中的採購機製到分散的私人支付方網路，這影響著新技術的採用速度和合約的複雜性。一些市場朝向以金額為準的合約模式的轉變，促使製藥公司在傳統的實證方案之外，也開始提供與療效掛鉤的提案。

靶向腫瘤學領域中塑造治療差異化、生命週期策略和合作機會的競爭定位和策略行動

Sunitinib領域的競爭格局呈現出成熟產品與新療法並存的局面，二者都對臨床定位與策略重點產生影響。成熟的製藥公司持續管理長期臨床安全性和有效性數據，而新藥則透過拓展適應症、提高耐受性或基於生物標記的療效聲明來凸顯自身優勢。此外，各公司也在強化自身的價值提案，並投資於真實世界數據（REW）的收集和核准後研究，以支持與支付者和醫療系統的談判。

為了確保永續地獲得治療和競爭優勢，我們需要一個切實可行的跨部門策略，將證據產生、市場進入和供應韌性整合起來。

行業領導企業應優先考慮整合臨床開發、市場進入和供應鏈韌性的整合策略，以確保患者用藥可及性和商業性永續性。這首先需要對每項適應症的臨床價值和真實世界療效進行嚴格評估，並輔以針對性證據，直接回應支付方的關切和治療特定亞組患者的臨床醫生的需求。同時，商業部門應針對第一線治療和後續治療建構差異化的宣傳策略，並根據醫院和專科診所的採購和製劑習慣，最佳化其針對不同機構的推廣方式。

我們高度透明和系統化的研究途徑，結合文獻綜述、專家訪談和質性檢驗，得出切實可行的見解。

本報告的研究結合了系統性的文獻整合、專家訪談和質性分析，建構了可靠的證據基礎。研究人員對同行評審的臨床文獻、監管文件和治療指南進行了深入審查，以闡明相關化合物的臨床背景、作用機制和適應症演變。此外，研究人員還與臨床醫生、醫保專家和供應鏈專家進行了結構化訪談，從而獲得了關於藥物使用模式、支付方關注點和營運挑戰的最新見解。

簡潔的整合強調了整合證據、獲取策略和營運準備的必要性，以確保持續的治療意義。

總之，在不斷發展的腫瘤治療領域，Sunitinib酸鹽仍然是一種具有臨床意義的選擇，而適應性強的商業和運作策略至關重要。複雜的診斷技術、不斷湧現的競爭療法以及支付方的嚴格審查，都要求製造商和合作夥伴認真考慮證據產生、相關人員參與以及供應鏈風險管理。針對不同適應症的生物學特性、治療方案預期以及醫院和專科診所的具體情況制定細分策略，對於維持其在不同市場的相關性和可近性至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：蘋果酸Sunitinib尼市場：依適應症分類

  • 胃腸道基質腫瘤
    • KIT變體
    • PDGRA 變體
    • 野生型
  • 胰臟神經內分泌腫瘤
    • 功能
    • 不具備功能
  • 腎臟細胞癌
    • 透明細胞癌
    • 非透明細胞癌

第9章：Sunitinib酸鹽市場：依治療階段分類

  • 一線治療
  • 二線治療
  • 三線治療

第10章：蘋果酸Sunitinib尼市場：依最終用戶分類

  • 醫院
  • 專科診所

第11章：蘋果酸Sunitinib尼市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：蘋果酸Sunitinib尼市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：蘋果酸Sunitinib尼市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：蘋果酸Sunitinib尼市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國舒尼替Sunitinib酸鹽市場

第16章：中國Sunitinib酸鹽市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aark Pharmaceuticals
  • Active BIoTech AB
  • Anant Pharmaceuticals Pvt. Ltd.
  • AstraZeneca PLC
  • Beijing Lunarsun Pharmaceutical Co., Ltd.
  • Bio-Techne Corporation
  • Brawn Laboratories Ltd.
  • Hetero Labs Limited
  • Hikma Pharmaceuticals PLC
  • JEIL PHARMACEUTICAL CO.,LTD.
  • Manus Aktteva Biopharma LLP
  • Medichem SA
  • Medzeel Lifescience
  • Nanjing First Pharmaceutical Co. Ltd
  • Natco Pharma Limited
  • Pfizer Inc.
  • Sichuan Xieli Pharmaceutical Co., Ltd.
  • Synthland Limited
  • Taj Pharma India Limited
  • TargetMol Chemicals Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-2A0283E25693

The Sunitinib Malate Market was valued at USD 148.43 million in 2025 and is projected to grow to USD 166.95 million in 2026, with a CAGR of 11.69%, reaching USD 322.01 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 148.43 million
Estimated Year [2026] USD 166.95 million
Forecast Year [2032] USD 322.01 million
CAGR (%) 11.69%

Clear and authoritative framing of sunitinib malate's therapeutic role and strategic considerations shaping clinical and commercial decisions in oncology

Sunitinib malate has established itself as a cornerstone targeted therapy across several oncologic indications, and recent clinical and commercial developments warrant a concise executive-level synthesis. This introduction frames the therapeutic profile of the compound, highlighting its multitargeted receptor tyrosine kinase inhibition and its clinical relevance in disorders where angiogenesis and oncogenic signaling are primary drivers of disease progression. The following analysis situates sunitinib within evolving treatment paradigms, regulatory dialogues, and stakeholder expectations while emphasizing the interplay between clinical evidence and commercial strategy.

Beyond mechanism of action, contextual factors shape product trajectories: evolving biomarker characterization, emergent competitor agents, and shifts in care delivery all influence how sunitinib is utilized across patient populations. The introduction outlines the scope of the subsequent sections, which cover transformational market shifts, policy impacts, granular segmentation insights, regional dynamics, competitor behavior, recommended actions, and the methodological approach underpinning the research. Together, these elements provide a cohesive vantage point for leaders evaluating therapeutic positioning, lifecycle management, and portfolio prioritization in oncology.

How converging advances in precision diagnostics, oral oncology care models, and payer evolution are redefining clinical positioning and commercial strategies

The landscape for targeted oncology therapies is undergoing transformative shifts that extend beyond new molecule introductions to encompass diagnostics, care delivery, and payer dynamics. Precision oncology continues to reorient treatment selection, with more granular genomic and phenotypic characterization driving differential utilization of agents like sunitinib across tumor subtypes. Parallel to biomarker advances, the rise of oral oncolytics has changed patient management paradigms, increasing the relevance of outpatient care pathways, medication adherence strategies, and remote monitoring technologies.

In addition, evolving competitive pressures-ranging from next-generation kinase inhibitors to combination regimens involving immune-oncology agents-are prompting reassessments of sunitinib's role in therapy sequences. Regulatory pathways and label amendments driven by new evidence can rapidly alter clinical positioning, and payers are responding with tighter utilization management and value-based contracting experiments. From a commercial perspective, these forces necessitate more sophisticated stakeholder engagement, adaptive market access strategies, and investment in real-world evidence to substantiate comparative effectiveness. Consequently, organizations must integrate clinical, regulatory, and payer intelligence to sustain therapeutic relevance and patient access.

Assessing the operational and commercial implications of United States tariff actions on supply chains, procurement, and market access resilience

The imposition of tariffs on pharmaceutical inputs and finished products originating from or transiting through the United States has practical implications for global supply chains and commercial operations. Where tariffs affect active pharmaceutical ingredients, finished formulations, or raw materials, manufacturers may confront increased production costs that ripple through procurement, manufacturing cadence, and inventory policies. In turn, commercial teams must reassess pricing strategies, contract negotiations with distributors, and shelf-price positioning in markets where contractual and regulatory constraints limit price flexibility.

Operational responses often include sourcing diversification, nearshoring of manufacturing, and renegotiation of supplier terms to mitigate exposure. These adjustments can introduce lead-time variability and transitional quality oversight requirements, necessitating strengthened supplier qualification processes. Health systems and specialty clinics may absorb cost increases differently than hospitals, which can affect the relative economics of distribution channels and formulary placements. Moreover, tariffs interact with regulatory frameworks and reimbursement rules, potentially complicating market access discussions.

Strategically, stakeholders should evaluate the tariff environment as a material factor in procurement risk assessments and contingency planning. Cross-functional teams combining procurement, regulatory affairs, and market access should model scenario pathways and identify mitigations that preserve both supply continuity and patient access without compromising quality or compliance.

In-depth segmentation revealing how indications, treatment lines, care settings, and distribution routes shape clinical use cases and commercial priorities

A nuanced segmentation framework illuminates how sunitinib's use and value proposition vary across clinical settings and commercial channels. Indication-level differentiation captures distinct biological subgroups and therapeutic intents: Gastrointestinal Stromal Tumor encompasses Kit mutant, PDGFRA mutant, and wild-type variants that respond differently to kinase inhibition, while Pancreatic Neuroendocrine Tumor divides into functional and nonfunctional presentations with divergent symptom burdens and treatment goals, and Renal Cell Carcinoma separates into clear cell and non-clear cell histologies with distinct prognostic and therapeutic profiles. These intra-indication strata influence clinical decision-making, trial design, and the design of companion diagnostic strategies.

Line-of-treatment segmentation reveals how first-line, second-line, and third-line settings demand different value narratives; early-line use emphasizes comparative efficacy and tolerability, whereas later-line positioning often relies on demonstrated benefit in refractory populations and manageable safety profiles. End-user segmentation differentiates settings of care-hospitals versus specialty clinics-each with unique procurement processes, prescribing behaviors, and patient support needs that shape access pathways. Finally, distribution channel distinction among hospital pharmacies, online pharmacies, and retail pharmacies has implications for adherence programs, reimbursement touchpoints, and the logistics of oral oncolytic delivery. Integrating these segmentation lenses supports targeted clinical development, commercial planning, and market access execution.

How regional regulatory diversity, payer models, and distribution infrastructure drive differentiated access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a pronounced influence on regulatory pathways, reimbursement norms, and stakeholder expectations across the globe. In the Americas, regulatory authorities and payers emphasize comparative clinical benefit and cost-effectiveness, while health systems vary from highly centralized procurement mechanisms to decentralized private payer networks, affecting adoption cadence and contracting complexity. Shifts toward value-based arrangements in some markets are prompting manufacturers to present outcomes-linked propositions alongside traditional evidence packages.

Across Europe, Middle East & Africa, heterogeneity in regulatory frameworks and health technology assessment standards creates a mosaic of access timelines and evidence requirements. Pricing negotiations and reimbursement decisions in these regions frequently hinge on external reference pricing and national clinical guidelines, so localized evidence generation and stakeholder engagement remain essential. In Asia-Pacific, accelerated regulatory pathways and expanding clinical trial ecosystems coexist with diverse payer landscapes; some jurisdictions are rapidly adopting innovative access schemes while others maintain conservative reimbursement criteria. Differences in manufacturing capacity, distribution infrastructure, and patient care models across regions necessitate tailored commercialization approaches that account for regulatory alignment, supply logistics, and localized evidence needs.

Competitive positioning and strategic behaviors shaping therapeutic differentiation, lifecycle initiatives, and partnership opportunities in targeted oncology

Competitive dynamics in the sunitinib landscape reflect a mix of legacy incumbency and new therapeutic entrants, each influencing clinical positioning and strategic priorities. Established manufacturers continue to steward long-term clinical safety and efficacy data, while newer agents pursue label extensions, improved tolerability, or biomarker-driven claims to differentiate themselves. Companies are also investing in real-world evidence generation and post-approval studies to reinforce value propositions and to support negotiations with payers and health systems.

Commercial behavior spans lifecycle management tactics such as indication expansion strategies, formation of patient support programs for oral therapy adherence, and partnerships to enhance distribution reach. On the manufacturing front, firms are optimizing capacity and supply resilience to reduce vulnerability to procurement disruptions and tariff-related cost pressures. Strategic collaborations with diagnostic developers and academic consortia are increasingly common, seeking to align therapeutic use with emerging precision oncology paradigms. For stakeholders evaluating partnerships or competitive responses, the emphasis should be on complementary capabilities in clinical evidence generation, market access expertise, and operational agility.

Actionable cross-functional strategies to align evidence generation, market access, and supply resilience for sustained therapeutic access and competitive advantage

Industry leaders should prioritize integrated strategies that align clinical development, market access, and supply chain resilience to preserve patient access and commercial viability. Initiatives should begin with a rigorous assessment of indication-specific clinical value and real-world performance, complemented by targeted evidence generation that speaks directly to payer concerns and to clinicians treating distinct subpopulations. In parallel, commercial teams should develop differentiated narratives for first-line versus later-line use and tailor engagement to hospitals and specialty clinics based on their procurement and prescribing behaviors.

Operationally, leaders must diversify sourcing and strengthen supplier qualification to reduce exposure to tariff and trade disruptions, while also investing in distribution strategies that leverage hospital pharmacies, retail partners, and secure online dispensing models to reach patients safely and efficiently. Collaborative approaches with diagnostic providers can sharpen patient selection and improve the likelihood of favorable reimbursement decisions. Finally, adopting adaptive pricing and contracting mechanisms, including outcomes-based agreements where feasible, will support constructive dialogues with payers and sustain access in value-conscious environments. Acting on these priorities will require cross-functional governance and a commitment to agile execution.

Transparent and methodical research approach combining literature review, expert interviews, and qualitative triangulation to derive actionable insights

The research underpinning this report combines systematic literature synthesis, expert interviews, and qualitative analysis to build a robust evidence base. Peer-reviewed clinical literature, regulatory documents, and treatment guidelines were reviewed to establish the clinical context, mechanism of action, and label histories relevant to the compound. In addition, structured interviews with clinicians, reimbursement experts, and supply chain professionals provided contemporary perspectives on utilization patterns, payer concerns, and operational challenges.

Analytical methods emphasized triangulation across sources to validate key themes and to identify areas of consensus and divergence. The research process involved mapping segmentation lenses-indication subtypes, line-of-treatment contexts, care settings, and distribution channels-to observed behaviors in practice and to emergent commercial tactics. Care was taken to ensure that conclusions reflected qualitative evidence and expert judgment without relying on proprietary datasets. Transparency about assumptions and methodological constraints was maintained, and stakeholders can request methodological appendices or interview summaries to better understand the provenance of specific insights.

Concise synthesis highlighting the imperative for integrated evidence, access strategies, and operational preparedness to secure sustained therapeutic relevance

In conclusion, sunitinib malate remains a clinically meaningful option within a shifting oncology ecosystem that demands adaptive commercial and operational approaches. The interplay of precision diagnostics, evolving therapeutic competitors, and payer scrutiny requires manufacturers and partners to be deliberate about evidence generation, stakeholder engagement, and supply chain risk management. Segment-specific strategies-attuned to indication biology, line-of-treatment expectations, and the nuances of hospitals versus specialty clinics-will be essential to maintain relevance and access across diverse markets.

Furthermore, external forces such as tariff regimes and regional regulatory heterogeneity underscore the need for proactive procurement and market access planning. By aligning clinical strategy with pragmatic operational measures and by fostering collaborative relationships with diagnostic providers and health systems, organizations can better navigate uncertainties and protect patient access. Ultimately, success will hinge on an integrated approach that balances scientific rigor, commercial acumen, and operational resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sunitinib Malate Market, by Indication

  • 8.1. Gastrointestinal Stromal Tumor
    • 8.1.1. Kit Mutant
    • 8.1.2. Pdgra Mutant
    • 8.1.3. Wild Type
  • 8.2. Pancreatic Neuroendocrine Tumor
    • 8.2.1. Functional
    • 8.2.2. Non Functional
  • 8.3. Renal Cell Carcinoma
    • 8.3.1. Clear Cell Carcinoma
    • 8.3.2. Non-Clear Cell Carcinoma

9. Sunitinib Malate Market, by Line Of Treatment

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line

10. Sunitinib Malate Market, by End User

  • 10.1. Hospital
  • 10.2. Specialty Clinic

11. Sunitinib Malate Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Sunitinib Malate Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Sunitinib Malate Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Sunitinib Malate Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Sunitinib Malate Market

16. China Sunitinib Malate Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aark Pharmaceuticals
  • 17.6. Active Biotech AB
  • 17.7. Anant Pharmaceuticals Pvt. Ltd.
  • 17.8. AstraZeneca PLC
  • 17.9. Beijing Lunarsun Pharmaceutical Co., Ltd.
  • 17.10. Bio-Techne Corporation
  • 17.11. Brawn Laboratories Ltd.
  • 17.12. Hetero Labs Limited
  • 17.13. Hikma Pharmaceuticals PLC
  • 17.14. JEIL PHARMACEUTICAL CO.,LTD.
  • 17.15. Manus Aktteva Biopharma LLP
  • 17.16. Medichem S.A.
  • 17.17. Medzeel Lifescience
  • 17.18. Nanjing First Pharmaceutical Co. Ltd,
  • 17.19. Natco Pharma Limited
  • 17.20. Pfizer Inc.
  • 17.21. Sichuan Xieli Pharmaceutical Co., Ltd.
  • 17.22. Synthland Limited
  • 17.23. Taj Pharma India Limited
  • 17.24. TargetMol Chemicals Inc.
  • 17.25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SUNITINIB MALATE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SUNITINIB MALATE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SUNITINIB MALATE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SUNITINIB MALATE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SUNITINIB MALATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS SUNITINIB MALATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GCC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 140. GCC SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 141. GCC SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 142. GCC SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 143. GCC SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GCC SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 164. G7 SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 165. G7 SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 166. G7 SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 167. G7 SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. G7 SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. NATO SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 172. NATO SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 173. NATO SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 174. NATO SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 175. NATO SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. NATO SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)